Other News

Cardiovascular Systems Presents Liberty 360° Two-Year Outcomes at 2018 Amputation Prevention Symposium

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented two-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago. The […]

CERENOVUS Receives European Regulatory Approval For BRAVO Flow Diverter to Treat Intracranial Aneurysms.

BRUSSELS–(BUSINESS WIRE)–CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, announced today it has received European CE mark approval for its BRAVO Flow Diverter. The device is approved for use in the treatment of patients suffering from intracranial aneurysms. The device will divert blood flow from the aneurysm and […]

BioAxone BioSciences Receives Notice of Allowance on Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–BioAxone BioSciences, Inc., a biotechnology company focused on developing innovative drugs to treat neurotrauma and neurovascular disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). The notice refers to a key patent application (US 15/590,815), which will […]

MyoKardia to Present at the 2018 Wedbush Pacgrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer,  will present at the 2018 Wedbush Pacgrow Healthcare Conference on Tuesday, August 14, 2018, at 10:55 a.m. […]

Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes

MONTREAL, Aug. 8, 2018 /PRNewswire/ — Milestone Pharmaceuticals, a clinical-stage cardiovascular company, today announced that the first patient has been randomized in its Phase 3 clinical study of etripamil. Etripamil is a new investigational, rapid-onset, short-acting calcium channel blocker administered intranasally by the patient designed to terminate paroxysmal supraventricular tachycardia (PSVT) episodes wherever […]

Boston Scientific Announces Agreement to Acquire VENITI, Inc.

MARLBOROUGH, Mass., Aug. 8, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire VENITI, Inc., a privately-held company in Fremont, California which has developed and commercialized the VICI VENOUS STENT® System for treating venous obstructive disease. Boston Scientific has been an investor in VENITI since 2016 and currently […]

PaceMate™ Partners with SeaMercy on Pacific Islands Healthcare Mission

BRADENTON, Fla.–(BUSINESS WIRE)–PaceMateTM announces today the volunteer partnership between CEO Kevin R. Campbell, MD, FACC, and SeaMercy, an Oregon-based charity committed to providing medical relief to underprivileged natives in the South Pacific. PaceMateTM is a compassion-driven digital healthcare company committed to providing fully integrated remote monitoring services for cardiac implantable electronic devices […]

InspireMD Reports 94% Increase in CGuard™ EPS Revenues for the Second Quarter of 2018

TEL AVIV, Israel, Aug. 06, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced results for the second quarter ending June 30, 2018. Second Quarter 2018 highlights: Revenues […]